News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
127,983 Results
Type
Article (8771)
Company Profile (28)
Press Release (119184)
Section
Business (38772)
Career Advice (330)
Deals (5703)
Drug Delivery (10)
Drug Development (11728)
Employer Resources (17)
FDA (3332)
Job Trends (3531)
News (61988)
Policy (6439)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (3)
2024 Bio NC Digital (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
Academia (964)
Academic (1)
Adcomms (1)
Allergies (17)
Alliances (12666)
ALS (6)
Alzheimer's disease (234)
Antibody-drug conjugate (ADC) (13)
Approvals (3373)
Artificial intelligence (46)
Automation (8)
Bankruptcy (40)
Best Places to Work (2738)
BIOSECURE Act (3)
Biosimilars (8)
Biotechnology (20)
Bladder cancer (10)
Brain cancer (4)
Breast cancer (50)
Cancer (379)
Cardiovascular disease (20)
Career advice (292)
Career pathing (5)
CAR-T (25)
Cell therapy (64)
Cervical cancer (8)
Clinical research (9054)
Collaboration (188)
Compensation (4)
Complete response letters (3)
COVID-19 (785)
CRISPR (10)
C-suite (28)
Cystic fibrosis (8)
Data (341)
Decentralized trials (1)
Denatured (3)
Depression (3)
Diabetes (26)
Diagnostics (3338)
Digital health (1)
Diversity, equity & inclusion (6)
Drug discovery (27)
Drug pricing (7)
Drug shortages (1)
Duchenne muscular dystrophy (17)
Earnings (10468)
Editorial (3)
Employer branding (3)
Employer resources (15)
Events (13457)
Executive appointments (123)
FDA (3506)
Featured Employer (4)
Frontotemporal dementia (2)
Funding (123)
Gene editing (13)
Generative AI (5)
Gene therapy (45)
GLP-1 (116)
Government (1148)
Grass and pollen (3)
Guidances (8)
Healthcare (2888)
Immunology and inflammation (8)
Indications (3)
Infectious disease (826)
Inflammatory bowel disease (11)
Influenza (21)
Intellectual property (16)
Interviews (56)
IPO (1807)
IRA (1)
Job creations (919)
Job search strategy (253)
Kidney cancer (1)
Labor market (3)
Layoffs (45)
Leadership (4)
Legal (1269)
Liver cancer (11)
Lung cancer (64)
Lymphoma (32)
Machine learning (1)
Management (3)
Manufacturing (60)
MASH (4)
Medical device (1835)
Medtech (1835)
Mergers & acquisitions (3976)
Metabolic disorders (57)
Multiple sclerosis (5)
NASH (1)
Neurodegenerative disease (14)
Neuropsychiatric disorders (2)
Neuroscience (278)
NextGen: Class of 2025 (1027)
Non-profit (859)
Northern California (297)
Now hiring (11)
Obesity (28)
Opinion (27)
Ovarian cancer (5)
Pain (11)
Pancreatic cancer (8)
Parkinson's disease (16)
Partnered (7)
Patents (24)
Patient recruitment (6)
Peanut (10)
People (12373)
Pharmaceutical (8)
Pharmacy benefit managers (1)
Phase I (2734)
Phase II (3645)
Phase III (3373)
Pipeline (137)
Podcasts (4)
Policy (11)
Postmarket research (444)
Preclinical (1526)
Press Release (37)
Prostate cancer (20)
Psychedelics (2)
Radiopharmaceuticals (37)
Rare diseases (45)
Real estate (2227)
Recruiting (6)
Regulatory (4387)
Reports (9)
Research institute (925)
Resumes & cover letters (41)
RNA editing (1)
RSV (8)
Schizophrenia (3)
Series A (16)
Series B (12)
Service/supplier (1)
Sickle cell disease (7)
Southern California (301)
Special edition (2)
Spinal muscular atrophy (44)
Sponsored (6)
Startups (851)
State (1)
Stomach cancer (2)
Supply chain (12)
United States (3295)
Vaccines (119)
Venture capitalists (5)
Webinars (1)
Weight loss (13)
Women's health (8)
Date
Today (18)
Last 7 days (86)
Last 30 days (380)
Last 365 days (5404)
2025 (1173)
2024 (5715)
2023 (6732)
2022 (10539)
2021 (11026)
2020 (10826)
2019 (7984)
2018 (6300)
2017 (6710)
2016 (6697)
2015 (7469)
2014 (5860)
2013 (5088)
2012 (5324)
2011 (5476)
2010 (4898)
Location
Africa (161)
Alabama (11)
Alaska (2)
Arizona (36)
Arkansas (2)
Asia (8244)
Australia (1344)
California (749)
Canada (301)
China (48)
Colorado (41)
Connecticut (53)
Delaware (26)
Europe (16933)
Florida (95)
Georgia (61)
Idaho (6)
Illinois (53)
India (3)
Indiana (40)
Iowa (2)
Japan (41)
Kansas (28)
Kentucky (4)
Louisiana (1)
Maine (23)
Maryland (120)
Massachusetts (474)
Michigan (60)
Minnesota (63)
Missouri (43)
Montana (10)
Nebraska (3)
Nevada (3)
New Hampshire (8)
New Jersey (335)
New Mexico (9)
New York (277)
North Carolina (162)
North Dakota (2)
Northern California (297)
Ohio (48)
Oklahoma (3)
Oregon (4)
Pennsylvania (156)
Rhode Island (11)
South America (219)
South Carolina (4)
Southern California (301)
Tennessee (21)
Texas (169)
Utah (41)
Virginia (25)
Washington D.C. (8)
Washington State (91)
West Virginia (1)
Wisconsin (13)
127,983 Results for "shin nippon biomedical laboratories".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amaran Biotech Signs MOU with Nippon Fine Chemical
March 7, 2025
·
3 min read
Gene therapy
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku
In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.
January 14, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 66th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.
June 13, 2024
·
6 min read
Press Releases
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
January 27, 2025
·
5 min read
Policy
Satsuma Fails to Secure FDA Approval for Nasal Powder Migraine Drug
The FDA’s Complete Response Letter identified problems with the drug candidate’s chemistry, manufacturing and controls, parent company Shin Nippon Biomedical Laboratories announced Thursday.
January 18, 2024
·
2 min read
·
Tristan Manalac
Business
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.
April 4, 2024
·
3 min read
Press Releases
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
November 13, 2024
·
5 min read
Press Releases
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
December 11, 2024
·
4 min read
Business
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
epitoMAP Inc. and Animal Allergy Clinical Laboratories Inc. entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. on November 10, 2023.
November 17, 2023
·
2 min read
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
Vicore Pharma Holding AB, unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize Vicore’s drug candidate C21 in Japan.
February 9, 2024
·
4 min read
1 of 12,799
Next